The DOI matches its Crossref record; 188 of the 195 references it cites were found in a registry or an index.
p53, cancer and the immune response
Open accessAbstract
The importance of cancer-cell-autonomous functions of the tumour suppressor p53 (encoded by TP53) has been established in many studies, but it is now clear that the p53 status of the cancer cell also has a profound impact on the immune response. Loss or mutation of p53 in cancers can affect the recruitment and activity of myeloid and T cells, allowing immune evasion and promoting cancer progression. p53 can also function in immune cells, resulting in various outcomes that can impede or support tumour development. Understanding the role of p53 in tumour and immune cells will help in the development of therapeutic approaches that can harness the differential p53 status of cancers compared with most normal tissue.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These mutations can affect the tumor immune microenvironment (TIME) by altering cytokine expression and regulating the tumor’s sensitivity to immune checkpoint inhibitors.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [610]
In the citing paper
“It is widely accepted that gene mutations, including those affecting undruggable proteins, have a significant impact on the efficacy of cancer immunotherapy.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [610]
In the citing paper
“For examples, cancer cells with functional wild-type genes tend to have a desirable cancer-restrictive TIME, while an imbalance in their expression can create a cancer-supportive TIME.610,611”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [610]
In the citing paper
“In brief, the status of genes can influence tumor cells not only through the impact of wild-type gene loss but also through their effects on the TIME.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [610]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Helicobacter pylori Infection and the Development of Gastric Cancer
Uemura, N., Okamoto, S., Yamamoto, S., Matsumura, N., Yamaguchi, S., Yamakido, M., Taniyama, K., Sasaki, N., & Schlemper, R. J. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa001999 · Cited by 4,492
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163
Self-citationIFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751
Mutations in the p53 gene occur in diverse human tumour types
Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hosteller, R., Cleary, K. R., Signer, S. H., Davidson, N. E., Baylin, S., Devilee, P., et al. (1989) · Nature · doi:10.1038/342705a0 · Cited by 2,730
Hallmarks of Cellular Senescence
Hernandez-Segura, A., Nehme, J., & Demaria, M. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.02.001 · Cited by 2,605
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Vousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,351
Self-citationHypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J. (1996) · Nature · doi:10.1038/379088a0 · Cited by 2,300
A complex secretory program orchestrated by the inflammasome controls paracrine senescence
Acosta, J. C., Banito, A., Wuestefeld, T., Georgilis, A., Janich, P., Morton, J. P., Athineos, D., Kang, T.-W., Lasitschka, F., Andrulis, M., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2784 · Cited by 2,278
Regulation and Function of the PD-L1 Checkpoint
Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,248
Targeting macrophages: therapeutic approaches in cancer
Cassetta, L., & Pollard, J. W. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.169 · Cited by 2,101
Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas
Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., vanTuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura, Y., et al. (1989) · Science · doi:10.1126/science.2649981 · Cited by 2,097
Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6
Yonish-Rouach, E., Resnftzky, D., Lotem, J., Sachs, L., Kimchi, A., & Oren, M. (1991) · Nature · doi:10.1038/352345a0 · Cited by 2,079
The diverse functions of the PD1 inhibitory pathway
Sharpe, A. H., & Pauken, K. E. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.108 · Cited by 2,054
Senescence of Activated Stellate Cells Limits Liver Fibrosis
Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell · doi:10.1016/j.cell.2008.09.015 · Cited by 2,027
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
Chen, Z., Trotman, L. C., Shaffer, D., Lin, H.-K., Dotan, Z. A., Niki, M., Koutcher, J. A., Scher, H. I., Ludwig, T., Gerald, W., et al. (2005) · Nature · doi:10.1038/nature03918 · Cited by 1,993
Kastenhuber, E. R., & Lowe, S. W. (2017) · Cell · doi:10.1016/j.cell.2017.08.028 · Cited by 1,906
Pathways of Antigen Processing
Blum, J. S., Wearsch, P. A., & Cresswell, P. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095910 · Cited by 1,635
Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
Togashi, Y., Shitara, K., & Nishikawa, H. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0175-7 · Cited by 1,620
AMP-activated protein kinase induces a p53-dependent metabolic checkpoint
Jones, R. G., Plas, D. R., Kubek, S., Buzzai, M., Mu, J., Xu, Y., Birnbaum, M. J., & Thompson, C. B. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.03.027 · Cited by 1,619
Soft-Tissue Sarcomas, Breast Cancer, and Other Neoplasms
Li, F. P., & FRAUMENI, J. F. (1969) · Annals of Internal Medicine · doi:10.7326/0003-4819-71-4-747 · Cited by 1,514
Intracellular Toll-like Receptors
Blasius, A. L., & Beutler, B. (2010) · Immunity · doi:10.1016/j.immuni.2010.03.012 · Cited by 1,392
Zhu, Y., Knolhoff, B. L., Meyer, M. A., Nywening, T. M., West, B. L., Luo, J., Wang-Gillam, A., Goedegebuure, S. P., Linehan, D. C., & DeNardo, D. G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3723 · Cited by 1,324
Mutant p53: one name, many proteinsPreprint
Freed-Pastor, W. A., & Prives, C. L. (2012) · Genes & Development · doi:10.1101/gad.190678.112 · Cited by 1,290
Mechanisms and functions of cellular senescence
Herranz, N., & Gil, J. (2018) · Journal of Clinical Investigation · doi:10.1172/jci95148 · Cited by 1,232
Hallmarks of cancer: Interactions with the tumor stroma
Pietras, K., & Östman, A. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.02.045 · Cited by 1,187
Regulation of NF-κB by TNF family cytokines
Hayden, M. S., & Ghosh, S. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.05.004 · Cited by 1,167
P53 in survival, death and metabolic health: a lifeguard with a licence to kill.
Kruiswijk, F., Labuschagne, C. F., & Vousden, K. H. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4007 · Cited by 1,080
Self-citationRegulation of Cutaneous Malignancy by γδ T Cells
Girardi, M., Oppenheim, D. E., Steele, C. R., Lewis, J. M., Glusac, E. J., Filler, R. B., Hobby, P., Sutton, B. J., Tigelaar, R. E., & Hayday, A. (2001) · Science · doi:10.1126/science.1063916 · Cited by 1,068
Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells
Maddocks, O. D. K., Berkers, C. R., Mason, S. M., Zheng, L., Blyth, K., Gottlieb, E., & Vousden, K. H. (2013) · Nature · doi:10.1038/nature11743 · Cited by 1,007
Self-citationDong, Z.-Y., Zhong, W.-Z., Zhang, X.-C., Su, J., Xie, Z., Liu, S.-Y., Tu, H.-Y., Chen, H.-J., Sun, Y.-L., Zhou, Q., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2554 · Cited by 959
Neoantigen-directed immune escape in lung cancer evolution
The TRACERx consortium, Rosenthal, R., Cadieux, E. L., Salgado, R., Bakir, M. A., Moore, D. A., Hiley, C. T., Lund, T., Tanić, M., Reading, J. L., et al. (2019) · Nature · doi:10.1038/s41586-019-1032-7 · Cited by 946
Agarwal, M. L., Agarwal, A., Taylor, W. R., & Stark, G. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.18.8493 · Cited by 858
Nelson, W. G., & Kastan, M. B. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.3.1815 · Cited by 855
Takaoka, A., Hayakawa, S., Yanai, H., Stoiber, D., Negishi, H., Kikuchi, H., Sasaki, S., Imai, K., Shibue, T., Honda, K., et al. (2003) · Nature · doi:10.1038/nature01850 · Cited by 847
Differential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells
Smyth, M. J., Thia, K. Y. T., Street, S. E. A., Cretney, E., Trapani, J. A., Taniguchi, M., Kawano, T., Pelikan, S. B., Crowe, N. Y., & Godfrey, D. I. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.4.661 · Cited by 831
Senescence and aging: the critical roles of p53
Rufini, A., Tucci, P., Celardo, I., & Melino, G. (2013) · Oncogene · doi:10.1038/onc.2012.640 · Cited by 798
Non-Cell-Autonomous Tumor Suppression by p53
Lujambio, A., Akkari, L., Simon, J., Grace, D., Tschaharganeh, D. F., Bolden, J. E., Zhao, Z., Thapar, V., Joyce, J. A., Krizhanovsky, V., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.020 · Cited by 766 · cited 1×
“This response attracts NK and myeloid cells that can function to remove damaged hepatocytes and so limit fibrosis, cirrhosis and HCC development (Krizhanovsky et al., 2008; Lujambio et al., 2013) (Fig.”
BackgroundPDL1 Regulation by p53 via miR-34
Cortez, M. A., Ivan, C., Valdecanas, D., Wang, X., Peltier, H. J., Ye, Y., Araujo, L., Carbone, D. P., Shilo, K., Giri, D. K., et al. (2016) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv303 · Cited by 683
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
Coelho, M. A., de Carné Trécesson, S., Rana, S., Zecchin, D., Moore, C., Molina-Arcas, M., East, P., Spencer-Dene, B., Nye, E., Barnouin, K., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.11.016 · Cited by 653
A Proinflammatory Cytokine Inhibits P53 Tumor Suppressor Activity
Hudson, J. D., Shoaibi, M. A., Maestro, R., Carnero, A., Hannon, G. J., & Beach, D. H. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.10.1375 · Cited by 649
Tumor-stroma interactions in pancreatic ductal adenocarcinoma
Mahadevan, D., & Hoff, D. D. V. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0686 · Cited by 619
Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment
Fu, C., & Jiang, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03059 · Cited by 618
Graeber, T. G., Peterson, J., Tsai, M., Monica, K., Fornace, A. J., & Giaccia, A. J. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.9.6264 · Cited by 617
Transcriptional Cross Talk between NF-κB and p53
Webster, G. A., & Perkins, N. D. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3485 · Cited by 598
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Arce Vargas, F., Furness, A. J. S., Litchfield, K., Joshi, K., Rosenthal, R., Ghorani, E., Solomon, I., Lesko, M. H., Ruef, N., Roddie, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.010 · Cited by 592
Leone, P., Shin, E.-C., Perosa, F., Vacca, A., Dammacco, F., & Racanelli, V. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt184 · Cited by 553
Myc Cooperates with Ras by Programming Inflammation and Immune Suppression
Kortlever, R. M., Sodir, N. M., Wilson, C. H., Burkhart, D. L., Pellegrinet, L., Brown Swigart, L., Littlewood, T. D., & Evan, G. I. (2017) · Cell · doi:10.1016/j.cell.2017.11.013 · Cited by 553
Linke, S. P., Clarkin, K., Leonardo, A. D., Tsou, A.-P., & Wahl, G. M. (1996) · Genes & Development · doi:10.1101/gad.10.8.934 · Cited by 531
Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis
Wellenstein, M. D., Coffelt, S. B., Duits, D. E. M., van Miltenburg, M. H., Slagter, M., de Rink, I., Henneman, L., Kas, S. M., Prekovic, S., Hau, C.-S., et al. (2019) · Nature · doi:10.1038/s41586-019-1450-6 · Cited by 500
Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246
Cooks, T., Pateras, I. S., Jenkins, L. M. M., Patel, K., Robles, A. I., Morris, J., Forshew, T., Appella, E., Gorgoulis, V. G., & Harris, C. C. (2018) · Nature Communications · doi:10.1038/s41467-018-03224-w · Cited by 497
Hussain, S. P., Amstad, P., Raja, K., Ambs, S., Nagashima, M., Bennett, W. P., Shields, P. G., Ham, A. L., Swenberg, J. A., Marrogi, A. J., et al. (2000) · PubMed · Cited by 482
Matsumoto, Y. M., Marusawa, H., Kinoshita, K., Endo, Y., Kou, T., Morisawa, T., Azuma, T., Okazaki, I., Honjo, T., & Chiba, T. (2007) · Nature Medicine · doi:10.1038/nm1566 · Cited by 480
Cooks, T., Pateras, I. S., Tarcic, O., Solomon, H., Schetter, A. J., Wilder, S., Lozano, G., Pikarsky, E., Forshew, T., Rozenfeld, N., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.03.022 · Cited by 478
Antonia, S. J., Mirza, N., Fricke, I., Chiappori, A., Thompson, P., Williams, N., Bepler, G., Simon, G., Janssen, W., Lee, J.-H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2013 · Cited by 444
黒瀬, 圭., Gilley, K., Matsumoto, S., Watson, P. H., Zhou, X.-P., & Eng, C. (2002) · Nature Genetics · doi:10.1038/ng1013 · Cited by 418
Iannello, A., Thompson, T. W., Ardolino, M., Lowe, S. W., & Raulet, D. H. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130783 · Cited by 414
Helicobacter pylori infection activates NF-kappa B in gastric epithelial cells
Keates, S. E., Hitti, Y., Upton, M. P., & Kelly, C. P. (1997) · Gastroenterology · doi:10.1053/gast.1997.v113.pm9322504 · Cited by 414
Role of Stat3 in Regulating p53 Expression and Function
Niu, G., Wright, K. L., Ma, Y., Wright, G. M., Huang, M., Irby, R., Briggs, J., Karras, J. G., Cress, W. D., Pardoll, D. M., et al. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.17.7432-7440.2005 · Cited by 404
Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer
Di Mitri, D., Toso, A., Chen, J. J., Sarti, M., Pinton, S., Jost, T. R., D’Antuono, R., Montani, E., Garcia-Escudero, R., Guccini, I., et al. (2014) · Nature · doi:10.1038/nature13638 · Cited by 388
Lacroix, M., Riscal, R., Arena, G., Linares, L. K., & Cam, L. L. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.10.002 · Cited by 376
Ren, G., Zhao, X., Wang, Y., Zhang, X., Chen, X., Xu, C., Yuan, Z.-R., Roberts, A. I., Zhang, L., Zheng, H. B., et al. (2012) · Cell stem cell · doi:10.1016/j.stem.2012.08.013 · Cited by 371
DiLillo, D. J., Yanaba, K., & Tedder, T. F. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903009 · Cited by 361
Biton, J., Mansuet‐Lupo, A., Pécuchet, N., Alifano, M., Ouakrim, H., Arrondeau, J., Boudou, P., Goldwasser, F., Leroy, K., Goc, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0163 · Cited by 360
Nitric oxide-induced cellular stress and p53 activation in chronic inflammation
Hofseth, L. J., Saito, S., Hussain, S. P., Espey, M. G., Miranda, K. M., Araki, Y., Jhappan, C., Higashimoto, Y., He, P., Linke, S. P., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0237083100 · Cited by 355
NKG2D function protects the host from tumor initiation
Smyth, M. J., Swann, J. B., Cretney, E., Zerafa, N., Yokoyama, W. M., & Hayakawa, Y. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050994 · Cited by 344
Immunological Surveillance in Neoplasia
Burnet, F. M. (1971) · Immunological Reviews · doi:10.1111/j.1600-065x.1971.tb00461.x · Cited by 343
Selective Evolution of Stromal Mesenchyme with p53 Loss in Response to Epithelial Tumorigenesis
Hill, R., Song, Y., Cardiff, R. D., & Van Dyke, T. (2005) · Cell · doi:10.1016/j.cell.2005.09.030 · Cited by 324
Serum p53 antibodies as early markers of lung cancer
Lubin, R., Zalcman, G., Bouchet, L., Trédaniel, J., Legros, Y., Cazals-Hatem, D. L., Hirsch, A., & Soussi, T. (1995) · Nature Medicine · doi:10.1038/nm0795-701 · Cited by 317
Kim, M. P., & Lozano, G. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.185 · Cited by 313
Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060301 · Cited by 302 · cited 1×
“The SASP molecules can attract both anti- and pro-tumorigenic immune populations, depending on the cancer type and mechanism of senescence (Coppé et al., 2008; Herranz and Gil, 2018).”
BackgroundBreast-Cancer Stromal Cells with TP53 Mutations and Nodal Metastases
Patócs, A., Zhang, L., Xu, Y., Weber, F., Caldés, T., Mutter, G. L., Platzer, P., & Eng, C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071825 · Cited by 297
The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting
Fingerle‐Rowson, G., Petrenko, O., Metz, C. N., Forsthuber, T. G., Mitchell, R. A., Huss, R., Moll, U. M., Müller, W., & Bucala, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533295100 · Cited by 284
Wörmann, S. M., Song, L., Ai, J., Diakopoulos, K. N., Kurkowski, M. U., Görgülü, K., Ruess, D. A., Campbell, A. D., Doglioni, C., Jodrell, D. I., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.03.010 · Cited by 282
Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers.
Davidoff, A. M., Iglehart, J. D., & Marks, J. R. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.8.3439 · Cited by 276
Schlichtholz, B., Legros, Y., Gillet, D., Fruchart‐Gaillard, C., Marty, M. E., Lane, D. P., Calvo, F. M., & Soussi, T. (1992) · PubMed · Cited by 276
Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers
Malekzadeh, P., Pasetto, A., Robbins, P. F., Parkhurst, M. R., Paria, B. C., Jia, L., Gartner, J. J., Hill, V. K., Yu, Z., Restifo, N. P., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci123791 · Cited by 274
Ponzetta, A., Carriero, R., Carnevale, S., Barbagallo, M., Molgora, M., Perucchini, C., Magrini, E. I., Gianni, F., Kunderfranco, P., Polentarutti, N., et al. (2019) · Cell · doi:10.1016/j.cell.2019.05.047 · Cited by 258
Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines.
Mayordomo, J. I., Loftus, D. J., Sakamoto, H., Cesare, C. M. D., Appasamy, P. M., Lotze, M. T., Storkus, W. J., Appella, E., & DeLeo, A. B. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.4.1357 · Cited by 253
p53 is a suppressor of inflammatory response in mice
Komarova, E. A., Krivokrysenko, V. I., Wang, K., Neznanov, N., Chernov, M. V., Komarov, P. G., Brennan, M., Golovkina, T. V., Rokhlin, O. W., Kuprash, D. V., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-3213fje · Cited by 247
Walton, J. B., Blagih, J., Ennis, D. P., Leung, E. Y. L., Dowson, S., Farquharson, M., Tookman, L. A., Orange, C., Athineos, D., Mason, S. M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1272 · Cited by 236
Self-citationDeconstructing networks of p53-mediated tumor suppression in vivo
Kaiser, A. M., & Attardi, L. D. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.171 · Cited by 232
A Role for p53 in the Adaptation to Glutamine Starvation through the Expression of SLC1A3
Tajan, M., Hock, A. K., Blagih, J., Robertson, N. A., Labuschagne, C. F., Kruiswijk, F., Humpton, T. J., Adams, P. D., & Vousden, K. H. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.07.005 · Cited by 230
Self-citationControl of metabolism by p53 – Cancer and beyond
Labuschagne, C. F., Zani, F., & Vousden, K. H. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.06.001 · Cited by 227
Self-citationInterleukin 6 Supports the Maintenance of p53 Tumor Suppressor Gene Promoter Methylation
Hodge, D. R., Peng, B. H., Cherry, J. C., Hurt, E. M., Fox, S. D., Kelley, J. A., Munroe, D. J., & Farrar, W. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3589 · Cited by 226
Candido, J. B., Morton, J. P., Bailey, P., Campbell, A. D., Karim, S. A., Jamieson, T., Lapienyte, L., Gopinathan, A., Clark, W., McGhee, E. J., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.131 · Cited by 224
Neutrophil-induced genomic instability impedes resolution of inflammation and wound healing
Butin‐Israeli, V., Bui, T. M., Wiesolek, H. L., Mascarenhas, L., Lee, J. J., Mehl, L. C., Knutson, K. R., Adam, S. A., Goldman, R. D., Beyder, A., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci122085 · Cited by 224
Textor, S., Fiegler, N., Arnold, A., Porgador, A., Hofmann, T. G., & Cerwenka, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3211 · Cited by 221
The Macrophage Colony-Stimulating Factor 1 Response Signature in Breast Carcinoma
Beck, A. H., Espinosa, Í., Edris, B., Li, R., Montgomery, K. D., Zhu, S., Varma, S., Marinelli, R. J., van de Rijn, M., & West, R. B. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1283 · Cited by 211
On immunosurveillance in human cancer.
Thomas, L. (1983) · PubMed · Cited by 210
Tumor Eradication by Wild-type p53-specific Cytotoxic T Lymphocytes
Vierboom, M., Nijman, H. W., Offringa, R., van der Voort, E. I. H., van Hall, T., van den Broek, L., Fleuren, G. J., Kenemans, P., Kast, W. M., & Melief, C. J. M. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.5.695 · Cited by 206
Mutant p53 Enhances Nuclear Factor κB Activation by Tumor Necrosis Factor α in Cancer Cells
Weisz, L., Damalas, A., Liontos, M., Karakaidos, P., Fontemaggi, G., Maor-Aloni, R., Kalis, M. L., Levrero, M., Strano, S., Gorgoulis, V. G., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2425 · Cited by 205
Heinemann, A., Zhao, F., Pechlivanis, S., Eberle, J., Steinle, A., Diederichs, S., Schadendorf, D., & Paschen, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1977 · Cited by 189
Current issues and perspectives in PD-1 blockade cancer immunotherapy
Chamoto, K., Hatae, R., & Honjo, T. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01588-7 · Cited by 188
Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms
Bezzi, M., Seitzer, N., Ishikawa, T., Reschke, M., Chen, M., Wang, G., Mitchell, C., Ng, C., Katon, J. M., Lunardi, A., et al. (2018) · Nature Medicine · doi:10.1038/nm.4463 · Cited by 179
p53 and NF-κB Coregulate Proinflammatory Gene Responses in Human Macrophages
Lowe, J. M., Menéndez, D., Bushel, P. R., Shatz, M., Kirk, E. L., Troester, M. A., Garantziotis, S., Fessler, M. B., & Resnick, M. A. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1070 · Cited by 176
Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses
Blagih, J., Zani, F., Chakravarty, P., Hennequart, M., Pilley, S. E., Hobor, S., Hock, A. K., Walton, J. B., Morton, J. P., Gronroos, E. C., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2019.12.028 · Cited by 175
Self-citationA mouse mutant p53 product recognized by CD4+ and CD8+ T cells.
Noguchi, Y., Chen, Y., & Old, L. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.3171 · Cited by 173
A unique role for p53 in the regulation of M2 macrophage polarization
Li, L., Ng, D. S. W., Mah, W.-C., Almeida, F. F., Rahmat, S. A. B., Rao, V. K., Leow, S. C., Laudisi, F., Peh, M. T., Goh, A. M., et al. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.212 · Cited by 169
Guo, G., Yu, M., Xiao, W., Celis, E., & Cui, Y. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2832 · Cited by 168
Brazil, J. C., Louis, N. A., & Parkos, C. A. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e318281f54e · Cited by 164
Ehrlich, P. F. (1913) · BMJ · doi:10.1136/bmj.2.2746.353 · Cited by 161
Cha, Y. J., Kim, H. R., Lee, C. Y., Cho, B. C., & Shim, H. S. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.05.001 · Cited by 158
p53 increases MHC class I expression by upregulating the endoplasmic reticulum aminopeptidase ERAP1
Wang, B., Niu, D., Lai, L., & Ren, E. C. (2013) · Nature Communications · doi:10.1038/ncomms3359 · Cited by 156
p53-mediated repression of nuclear factor-kappaB RelA via the transcriptional integrator p300.
Ravi, R. K., Mookerjee, B., van Hensbergen, Y., Bedi, G. C., Giordano, A., El‐Deiry, W. S., Fuchs, E. J., & Bedi, A. (1998) · PubMed · Cited by 156
Kitamura, T., Doughty-Shenton, D., Cassetta, L., Fragkogianni, S., Brownlie, D., Kato, Y., Carragher, N. O., & Pollard, J. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.02004 · Cited by 152
Antibody Immunity to the p53 Oncogenic Protein Is a Prognostic Indicator in Ovarian Cancer
Goodell, V., Salazar, L. G., Urban, N. D., Drescher, C. W., Gray, H. J., Swensen, R. E., McIntosh, M. W., & Disis, M. L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.2813 · Cited by 149
SOCS1 Links Cytokine Signaling to p53 and Senescence
Calabrese, V., Mallette, F. A., Deschênes‐Simard, X., Ramanathan, S., Gagnon, J., Moores, A., Ilangumaran, S., & Ferbeyre, G. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.09.044 · Cited by 146
Shatz, M., Menendez, D., & Resnick, M. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-4134 · Cited by 143
Leffers, N., Lambeck, A. J. A., Gooden, M. J. M., Hoogeboom, B. N., Wolf, R., Hamming, I. L. E., Hepkema, B. G., Willemse, P. H. B., Molmans, B. H. W., Hollema, H., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24597 · Cited by 143
Tumor Suppressor p53 Inhibits Autoimmune Inflammation and Macrophage Function
Zheng, S. J., Lamhamedi-Cherradi, S.-E., Wang, P., Xu, L., & Chen, Y. H. (2005) · Diabetes · doi:10.2337/diabetes.54.5.1423 · Cited by 142
Antibodies against p53 are associated with poor prognosis of colorectal cancer
Houbiers, J. G. A., van der Burg, S., van de Watering, L., Tollenaar, R., Brand, A., van de Velde, C., & Melief, C. J. M. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.386 · Cited by 141
CCR5 Expression Influences the Progression of Human Breast Cancer in a p53-dependent Manner
Mañes, S., Mira, E., Colomer, R., Montero, S., Real, L. M., Gómez‐Moutón, C., Jiménez-Baranda, S., Garzón, A., Lacalle, R. A., Harshman, K., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030580 · Cited by 140
NKG2D signaling in cancer immunosurveillance
López‐Soto, A., Huergo-Zapico, L., Acebes‐Huerta, A., Villa-Álvarez, M., & Gonzalez, S. R. (2014) · International Journal of Cancer · doi:10.1002/ijc.28775 · Cited by 138
Hypoxia-induced p53 modulates both apoptosis and radiosensitivity via AKT
Leszczyńska, K. B., Foskolou, I. P., Abraham, A., Anbalagan, S., Tellier, C., Haider, S. A., Span, P. N., O’Neill, E. E., Buffa, F. M., & Hammond, E. M. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80402 · Cited by 135
p53: emerging roles in stem cells, development and beyond
Jain, A. K., & Barton, M. C. (2018) · Development · doi:10.1242/dev.158360 · Cited by 130
Li, H., Lakshmikanth, T., Garofalo, C., Enge, M., Spinnler, C., Anichini, A., Székely, L., Kärre, K., Carbone, E., & Selivanova, G. (2011) · Cell Cycle · doi:10.4161/cc.10.19.17630 · Cited by 123
p53 induces TAP1 and enhances the transport of MHC class I peptides
Zhu, K., Wang, J., Zhu, J., Jiang, J., Shou, J., & Chen, X. (1999) · Oncogene · doi:10.1038/sj.onc.1203235 · Cited by 121
Sharma, M. D., Rodrı́guez, P. C., Koehn, B. H., Baban, B., Cui, Y. R., Guo, G., Shimoda, M., Pacholczyk, R., Shi, H., Lee, E.-J., et al. (2018) · Immunity · doi:10.1016/j.immuni.2017.12.014 · Cited by 121
Bacillus Calmette-Guérin mycobacteria stimulate human blood dendritic cells
Thurnher, M., Ramoner, R. E., Gastl, G. A., Radmayr, C., Böck, G., Herold, M., Klocker, H., & Bartsch, G. H. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970106)70:1 · Cited by 120
Pathologies Associated with the p53 ResponsePreprint
Gudkov, A. V., & Komarova, E. A. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001180 · Cited by 119
Roth, J., Dittmer, D. P., Réa, D., Tartaglia, J., Paoletti, E., & Levine, A. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.10.4781 · Cited by 118
Policing of oncogene activity by p53
Efeyan, A., García-Cao, I., Herranz, D., Velasco-Miguel, S., & Serrano, M. (2006) · Nature · doi:10.1038/443159a · Cited by 116
Hernández, J., Lee, P. P., Davis, M. M., & Sherman, L. A. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.2.596 · Cited by 110
p53 Status in Stromal Fibroblasts Modulates Tumor Growth in an SDF1-Dependent Manner
Addadi, Y., Moskovits, N. B.-C., Granot, D., Lozano, G., Carmi, Y., Apte, R. N., Neeman, M., & Oren, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1146 · Cited by 109
Mehta, S., Christopherson, K. W., Bhat‐Nakshatri, P., Goulet, R. J., Broxmeyer, H. E., Kopelovich, L., & Nakshatri, H. (2006) · Oncogene · doi:10.1038/sj.onc.1210120 · Cited by 109
Mutant p53 shapes the enhancer landscape of cancer cells in response to chronic immune signaling
Rahnamoun, H., Lu, H., Duttke, S. H. C., Benner, C. W., Glass, C. K., & Lauberth, S. M. (2017) · Nature Communications · doi:10.1038/s41467-017-01117-y · Cited by 103
Hoffmann, T. K., Donnenberg, A. D., Finkelstein, S. D., Donnenberg, V. S., Friebe-Hoffmann, U., Myers, E. N., Appella, E., DeLeo, A. B., & Whiteside, T. L. (2002) · PubMed · Cited by 103
Schauer, I. G., Zhang, J., Xing, Z., Guo, X. Q., Mercado‐Uribe, I., Sood, A. K., Huang, P., & Liu, J. (2013) · Neoplasia · doi:10.1593/neo.121228 · Cited by 102
Watanabe, M., Moon, K. D., Vacchio, M. S., Hathcock, K. S., & Hodes, R. J. (2014) · Immunity · doi:10.1016/j.immuni.2014.04.006 · Cited by 101
Lin, J., Tang, H., Jin, X., Jia, G., & Hsieh, J. (2002) · Oncogene · doi:10.1038/sj.onc.1205426 · Cited by 101
P53 and The Immune Response: 40 Years of Exploration—A Plan for the Future
Levine, A. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020541 · Cited by 97
Potentiation of a p53‐SLP vaccine by cyclophosphamide in ovarian cancer: A single‐arm phase II study
Vermeij, R., Leffers, N., Hoogeboom, B. N., Hamming, I. L. E., Wolf, R., Reyners, A. K. L., Molmans, B. H. W., Hollema, H., Bart, J., Drijfhout, J. W., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.27388 · Cited by 97
Role of toll-like receptors in tissue repair and tumorigenesis
Rakoff-Nahoum, S., & Medzhitov, R. M. (2008) · Biochemistry (Moscow) · doi:10.1134/s0006297908050088 · Cited by 91
Hoffmann, T. K., Nakano, K., Elder, E. M., Dworacki, G., Finkelstein, S. D., Appella, E., Whiteside, T. L., & DeLeo, A. B. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.10.5938 · Cited by 91
van der Burg, S. H., Menon, A. G., Redeker, A., Bonnet, M.-C., Drijfhout, J. W., Tollenaar, R. A. �. �., van de Velde, C. J. �., Moingeon, P. E., Kuppen, P. J. K., Offringa, R., et al. (2002) · PubMed · Cited by 90
Tumor Suppressor p53 Inhibits Systemic Autoimmune Diseases by Inducing Regulatory T Cells
Kawashima, H., Takatori, H., Suzuki, K., Iwata, A., Yokota, M., Suto, A., Minamino, T., Hirose, K., & Nakajima, H. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300509 · Cited by 84
Dijkgraaf, E. M., Santegoets, S. J. A. M., Reyners, A. K. L., Goedemans, R., Nijman, H. W., van Poelgeest, M. I. E., van Erkel, A. R., Smit, V. T. H. B. M., Daemen, T., van der Hoeven, J. J. M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4772 · Cited by 83
Nowak, D. G., Cho, H., Herzka, T. M., Watrud, K. E., DeMarco, D. V., Wang, V. M.-Y., Şentürk, Ş., Fellmann, C., Ding, D., Beinortas, T., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1113 · Cited by 83
Tran, T. Q., Lowman, X. H., Reid, M. A., Mendez‐Dorantes, C., Pan, M., Yang, Y., & Kong, M. (2016) · Oncogene · doi:10.1038/onc.2016.360 · Cited by 79
Espenschied, J. R., Lamont, J., Longmate, J., Pendas, S., Wang, Z., Diamond, D. J., & Ellenhorn, J. D. I. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.6.3401 · Cited by 79
Ubertini, V, Norelli, G., D'Arcangelo, D., Gurtner, A., Cesareo, E., Baldari, S., Gentileschi, M. P., Piaggio, G., Nisticò, P., Soddu, S., et al. (2015) · Oncogene · doi:10.1038/onc.2014.191 · Cited by 75
Campregher, C., Luciani, M. G., & Gasché, C. (2008) · Gut · doi:10.1136/gut.2007.141556 · Cited by 75
Volkmann, M., Müller, M., Hofmann, W. J., Meyer, M., Hagelstein, J., Räth, U., Kommerell, B., Zentgraf, H., & Galle, P. R. (1993) · Hepatology · doi:10.1002/hep.1840180313 · Cited by 70
Guo, G., Marrero, L., Rodrı́guez, P. C., Valle, L. D., Ochoa, A. C., & Cui, Y. R. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3810 · Cited by 69
Regulatory role of p53 in experimental autoimmune encephalomyelitis
Okuda, Y., Okuda, M., & Bernard, C. C. A. (2003) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(02)00428-9 · Cited by 69
Huang, Y., Yu, P., Li, W., Ren, G., Roberts, A. I., Cao, W., Zhang, X., Su, J., Chen, X., Chen, Q., et al. (2013) · Oncogene · doi:10.1038/onc.2013.355 · Cited by 68
Hardwick, N. R., Frankel, P., Ruel, C., Kilpatrick, J., Tsai, W., Kos, F., Kaltcheva, T., Leong, L., Morgan, R., Chung, V., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2709 · Cited by 66
Chiappori, A. A., Williams, C. C., Gray, J. E., Tanvetyanon, T., Haura, E. B., Creelan, B. C., Thapa, R., Chen, D.-T., Simon, G. R., Bepler, G., et al. (2019) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2287-9 · Cited by 64
He, X., Xiang, C., Zhang, C.-X., Xie, Y., Chen, L., Zhang, G.-X., Lu, Y., & Liu, G. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.09.045 · Cited by 64
Long‐term clinical and immunological effects of p53‐SLP® vaccine in patients with ovarian cancer
Leffers, N., Vermeij, R., Hoogeboom, B., Schulze, U. R., Wolf, R., Hamming, I. E., van der Zee, A. G., Melief, K. J., van der Burg, S. H., Daemen, T., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.25980 · Cited by 60
Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells.
Zwaveling, S., Vierboom, M., Mota, S. C. F., Hendriks, J. A., Ooms, M. E., Sutmuller, R. P. M., Franken, K. L. M. C., Nijman, H. W., OSSENDORP, F. A., van der Burg, S. H., et al. (2002) · PubMed · Cited by 60
Kennedy, S. R., Zhang, Y., & Risques, R. A. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.07.007 · Cited by 59
p53‐mediated adaptation to serine starvation is retained by a common tumour‐derived mutant
Humpton, T. J., Hock, A. K., Maddocks, O. D. K., & Vousden, K. H. (2018) · Cancer & Metabolism · doi:10.1186/s40170-018-0191-6 · Cited by 58
Self-citationZambetti, G. P., Olson, D., Labow, M., & Levine, A. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.9.3952 · Cited by 57
Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth
Narendran, A., Ganjavi, H., Morson, N., Connor, A. M., Barlow, J. W., Keystone, E. C., Malkin, D. M., & Freedman, M. H. (2003) · Experimental Hematology · doi:10.1016/s0301-472x(03)00159-0 · Cited by 56
Self-Tolerance Does Not Restrict the CD4+ T-Helper Response against the p53 Tumor Antigen
Lauwen, M. M., Zwaveling, S., de Quartel, L., Mota, S. C. F., Grashorn, J. C., Melief, C. J. M., van der Burg, S. H., & Offringa, R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3166 · Cited by 54
p19/Arf and p53 suppress sentinel lymph node lymphangiogenesis and carcinoma metastasis
Ruddell, A., Kelly‐Spratt, K. S., Furuya, M. H., Parghi, S. S., & Kemp, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210973 · Cited by 53
Translocation of the p53 gene in t(15;17) in acute promyelocytic leukaemia
Beau, M. M. L., Westbrook, C. A., Dı́az, M. O., Rowley, J. D., & Oren, M. (1985) · Nature · doi:10.1038/316826a0 · Cited by 53
Long story short: p53 mediates innate immunity
Miciak, J. J., & Bunz, F. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.03.001 · Cited by 49
p53-dependent expression of CXCR5 chemokine receptor in MCF-7 breast cancer cells
Mitkin, N. A., Hook, C., Schwartz, A. M., Biswas, S., Кочетков, Д. В., Muratova, A. M., Afanasyeva, M., Kravchenko, J. E., Bhattacharyya, A., & Kuprash, D. V. (2015) · Scientific Reports · doi:10.1038/srep09330 · Cited by 49
Menon, A. G., Kuppen, P. J. K., van der Burg, S. H., Offringa, R., Bonnet, M.-C., Harinck, B. I. J., Tollenaar, R. A. �. �., Redeker, A., Putter, H., Moingeon, P. E., et al. (2003) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700600 · Cited by 49
Trp53 negatively regulates autoimmunity via the STAT3‐Th17 axis
Zhang, S., Zheng, M., Kibe, R., Huang, Y., Marrero, L., Warren, S., Zieske, A. W., Iwakuma, T., Kolls, J. K., & Cui, Y. R. (2011) · The FASEB Journal · doi:10.1096/fj.10-175299 · Cited by 48
Daftarian, P. M., Song, G.-Y., Ali, S., Faynsod, M., Longmate, J., Diamond, D. J., & Ellenhorn, J. D. I. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0169 · Cited by 46
Lack of p53 Augments Antitumor Functions in Cytolytic T Cells
Banerjee, A., Thyagarajan, K., Chatterjee, S., Chakraborty, P., Kesarwani, P., Soloshchenko, M., Al-Hommrani, M., Andrijauskaite, K., Moxley, K. M., Janakiraman, H., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1798 · Cited by 38
Lambeck, A. J. A., Leffers, N., Hoogeboom, B. N., Sluiter, W. J., Hamming, I. L. E., Klip, H. G., ten Hoor, K. A., Esajas, M. D., van Oven, M., Drijfhout, J. W., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22710 · Cited by 34
Couch, M. E., Ferris, R. L., Brennan, J. A., Koch, W. M., Jaffee, E. M., Leibowitz, M. S., Nepom, G. T., Erlich, H. A., & Sidransky, D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0682 · Cited by 34
Control mechanisms in germ cells mediated by p53 family proteins
Gebel, J., Tuppi, M., Krauskopf, K., Coutandin, D., Pitzius, S., Kehrloesser, S., Osterburg, C., & Dötsch, V. (2017) · Journal of Cell Science · doi:10.1242/jcs.204859 · Cited by 33
Ligand dependent restoration of human TLR3 signaling and death in p53 mutant cells
Menendez, D., Lowe, J. M., Snipe, J., & Resnick, M. A. (2016) · Oncotarget · doi:10.18632/oncotarget.11210 · Cited by 31
CD4+ T Cell Responses to Self- and Mutated p53 Determinants During Tumorigenesis in Mice
Fedoseyeva, E. V., Boisgérault, F., Anosova, N. G., Wollish, W., Arlotta, P., Jensen, P. E., Ono, S. J., & Bénichou, G. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.11.5641 · Cited by 30
Angelopoulou, K., & Diamandis, E. P. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00295-x · Cited by 30
Shatz, M., Shats, I., Menendez, D., & Resnick, M. A. (2015) · Oncotarget · doi:10.18632/oncotarget.4435 · Cited by 29
Krüger, K., Büning, C., & Schriever, F. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(200101)31:1 · Cited by 27
Absence of p53 autoantibodies in sera from glioma patients.
Rainov, N. G., Dobberstein, K.-U., Fittkau, M., Bahn, H., Holzhausen, H. ‐., Gantchev, L. S., & Burkert, W. L. (1995) · PubMed · Cited by 24
Natural killer cells limit the clearance of senescent lung adenocarcinoma cells
Stokes, K. L., Cortez-Retamozo, V., Acosta, J., Lauderback, B., Robles-Oteiza, C., Cicchini, M., Pittet, M. J., & Feldser, D. M. (2019) · Oncogenesis · doi:10.1038/s41389-019-0133-3 · Cited by 21
Repression of the minimal hla-b promoter by c-myc and p53 occurs through independent mechanisms
Griffioen, M., Steegenga, W. T., Ouwerkerk, I. J. M., Peltenburg, L. T. C., Jochemsen, A. G., & Schrier, P. I. (1998) · Molecular Immunology · doi:10.1016/s0161-5890(98)00074-1 · Cited by 20
Sabapathy, K., & Nam, S. Y. (2008) · Cell Death and Differentiation · doi:10.1038/cdd.2008.55 · Cited by 19
Abdel‐Rahman, W. M., Aravind, S. R., Nair, V. A., Bajbouj, K., Valo, S., & Peltomäki, P. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-eacr25.46 · Cited by 19
Li, D., Hu, M., Liu, Y., Du, P., Du, P., Li, C.-S., Cheng, L., Liu, P., Jiang, J., Su, L., et al. (2018) · Cell Discovery · doi:10.1038/s41421-017-0007-9 · Cited by 18
Humoral immune response to p53 in malignant glioma
Weller, M., Ständer, M., Schabet, M., DICHGANS, J., Bornemann, A., & Meyermann, R. (1998) · Journal of Neurology · doi:10.1007/s004150050199 · Cited by 16
Primed for cancer: Li Fraumeni Syndrome and the pre-cancerous niche
Pantziarka, P. (2015) · ecancermedicalscience · doi:10.3332/ecancer.2015.541 · Cited by 15
Albers, A. E., Qian, X., Kaufmann, A. M., Mytilineos, D., Ferris, R. L., Hoffmann, T. K., & DeLeo, A. B. (2018) · Scientific Reports · doi:10.1038/s41598-018-29067-5 · Cited by 10
Cited by
Sorted by citations
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Drugging p53 in cancer: one protein, many targets
Hassin, O., & Oren, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00571-8 · Cited by 771
Understanding the complexity of p53 in a new era of tumor suppression
Liu, Y., Su, Z., Tavana, O., & Gu, W. J. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.04.009 · Cited by 538
Mutant p53 in cancer: from molecular mechanism to therapeutic modulation
Chen, X., Zhang, T., Su, W., Dou, Z., Zhao, D., Jin, X., Lei, H., Wang, J., Xie, X., Cheng, B., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05408-1 · Cited by 494
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
Metadata
- Authors
- Blagih, J., Buck, M. D., & Vousden, K. H.
- Affiliations
- The Francis Crick Institute (GB)
- Venue
- Journal of Cell Science
- Publisher
- The Company of Biologists
- Published
- 2020-03-01
- Volume
- 133
- Issue
- 5
- ISSN
- 0021-9533 (ISSN-L)
- 1477-9137
- OpenAlex
- W3009145316
- Cited by
- 333
- References
- 195
- Citations by year
- 2026: 27 · 2025: 48 · 2024: 63 · 2023: 63 · 2022: 63 · 2021: 51 · 2020: 18
- FWCI
- 5.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Cell Science (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- HighWire Press Open Archive (submittedVersion)
- The Francis Crick Institute (cc-by)
- Funders
- Cancer Research UK (C596/A26855, FC001557)
- Francis Crick Institute
- Medical Research Council (FC001557)
- Wellcome Trust (FC001557)
- Canadian Institutes of Health Research
- European Molecular Biology Organization (ALTF 1096-2018)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- p53, antitumor immunity, immune evasion, TP53 mutation, myeloid cells, T cells, tumor progression, cancer immunotherapy, cancer cells
- MeSH terms
- Humans, Immunity, Mutation, Neoplasms, Tumor Suppressor Protein p53
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
